Press release
Gallbladder Cancer Pipeline Insight Report 2023 (Updated) | Companies - Celgene, MedImmune, Ohara Pharmaceuticals, and Others
Gallbladder Cancer Pipeline
The research on the Gallbladder Cancer pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Gallbladder Cancer, any NDA approvals obtained for Gallbladder Cancer, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Gallbladder Cancer Pipeline treatment landscape of the report, click here @ Gallbladder Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Gallbladder Cancer Pipeline Report
• DelveInsight's Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Gallbladder Cancer Companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others.
• Promising Gallbladder Cancer Pipeline Therapies include M7824, Panitumumab, oxaliplatin, exatecan mesylate, ZD6474, Vandetanib, Gemcitabine, Capecitabine, Cisplatin, gemcitabine hydrochloride, and others.
• The Gallbladder Cancer companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The Gallbladder Cancer pipeline therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.
• Celgene' new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.
• Ohara Pharmaceutical's "breakthrough" drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.
Gallbladder Cancer Overview
Gallbladder cancer is a small, pear-shaped organ situated beneath the liver, responsible for storing bile enzymes and aiding in digestion. It is an uncommon form of cancer characterized by the abnormal growth of cells in the area of the gallbladder. The majority of gallbladder cancer cases originate from glandular cells that make up the inner lining of the organ.
For further information, refer to the detailed Gallbladder Cancer Unmet Needs, Gallbladder Cancer Market Drivers, and Gallbladder Cancer Market Barriers, click here for Gallbladder Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gallbladder Cancer Emerging Drugs Profile
• Durvalumab: Celgne
• ONC 201: Ohara Pharmaceuticals
Gallbladder Cancer Pipeline Therapeutics Assessment
There are approx. 10+ Gallbladder Cancer companies are developing Gallbladder Cancer therapies. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.
Request a sample and discover the recent advances in Gallbladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gallbladder Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gallbladder Cancer Pipeline Therapeutics Assessment
• Gallbladder Cancer Assessment by Product Type
• Gallbladder Cancer by Stage and Product Type
• Gallbladder Cancer Assessment by Route of Administration
• Gallbladder Cancer by Stage and Route of Administration
• Gallbladder Cancer Assessment by Molecule Type
• Gallbladder Cancer by Stage and Molecule Type
Some of the Companies in the Gallbladder Cancer Therapeutics Market include-
Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly, and Company, EMD Serono, and Others.
Dive deep into rich insights for drugs for Gallbladder Cancer Pipeline, click here @ Gallbladder Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gallbladder Cancer Pipeline Report
• Coverage- Global
• Gallbladder Cancer Companies- Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly and Company, EMD Serono, and Others
• Gallbladder Cancer Pipeline Therapies- cisplatin, gemcitabine hydrochloride, M7824, Gemcitabine, CTX-009, Paclitaxel, Fentanyl sublingual spray, and others
• Gallbladder Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Gallbladder Cancer Mergers and acquisitions, Gallbladder Cancer Licensing Activities @ Gallbladder Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Gallbladder Cancer Executive Summary
3. Gallbladder cancer: Overview
4. Gallbladder cancer Pipeline Therapeutics
5. Gallbladder cancer Therapeutic Assessment
6. Gallbladder cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Gallbladder cancer Collaboration Deals
9. Mid Stage Products (Phase II)
10. Durvalumab : Celgene
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. ONC 201: Ohara Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Gallbladder cancer Key Companies
17. Gallbladder cancer Key Products
18. Gallbladder cancer- Unmet Needs
19. Gallbladder cancer- Market Drivers and Barriers
20. Gallbladder cancer- Future Perspectives and Conclusion
21. Gallbladder cancer Analyst Views
22. Gallbladder cancer Key Companies
23. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gallbladder Cancer Pipeline Insight Report 2023 (Updated) | Companies - Celgene, MedImmune, Ohara Pharmaceuticals, and Others here
News-ID: 3162919 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Gallbladder
Gallbladder Cancer Epidemiology Forecast Insights
The Gallbladder Cancer Epidemiology Forecast has become an essential resource in modern healthcare, guiding clinicians, researchers, and policymakers as they work to understand a disease that often presents late and progresses rapidly. This type of forecast does not focus on financial figures or market performance; instead, it maps out the current and future landscape of gallbladder cancer occurrence, patterns, influential factors, and evolving patient needs. As gallbladder cancer remains one…
Gallbladder Surgery Under Dr. Moein in Los Angeles
Gallbladder surgery has become a preferred option for many in Los Angeles seeking relief from painful gallstones and cholecystitis. At Healthy Life Bariatrics, board-certified surgeon Dr. Babak Moein performs minimally invasive laparoscopic gallbladder removal, offering patients faster recovery, smaller incisions, and fewer complications.
More and more patients in Los Angeles are turning to minimally invasive gallbladder surgery to treat painful symptoms of gallstones and cholecystitis. Surgeons in the area, including trusted…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Cancer Treatment Market Expands With Emergence of Novel Chemotherape …
Gallbladder Cancer Treatment Market Overview
The Gallbladder Cancer Treatment Market is projected to grow from USD 720 Million in 2025 to USD 1.4 Billion by 2032, at a CAGR of 10.1% during the forecast period.
Coherent Market Insights is pleased to release its latest Gallbladder Cancer Treatment Market research report, offering an in-depth analysis of the U.S. Gallbladder Cancer Treatment Market Landscape from 2025 to 2032. This report delivers reliable projections across…
Gallbladder Cancer Market to Rise by 2032 | Celgene, MedImmune, Ohara Pharmaceut …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
Gallbladder Cancer Therapeutics Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Gallbladder Cancer Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Gallbladder Cancer Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
